Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[BRAF mutation was mainly detected in SSA/P with dysplasia (95%), SSA/P (85%), microvesicular HP (76%), and traditional serrated adenoma (54%), whereas KRAS mutation was present mainly in goblet cell HP (50%) and in tubulovillous adenoma (45%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP527734.RAWU40RTVYr4mp1Xfbcl-DRb5X9TXEC-GRpXOlDPzX6gY130_assertion description "[BRAF mutation was mainly detected in SSA/P with dysplasia (95%), SSA/P (85%), microvesicular HP (76%), and traditional serrated adenoma (54%), whereas KRAS mutation was present mainly in goblet cell HP (50%) and in tubulovillous adenoma (45%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP527734.RAWU40RTVYr4mp1Xfbcl-DRb5X9TXEC-GRpXOlDPzX6gY130_provenance.
• NP272397.RAS1NoGWB3wxTqlbkmqHUllt6qGivLscGTCxxF-wIlYM8130_assertion description "[BRAF mutation was mainly detected in SSA/P with dysplasia (95%), SSA/P (85%), microvesicular HP (76%), and traditional serrated adenoma (54%), whereas KRAS mutation was present mainly in goblet cell HP (50%) and in tubulovillous adenoma (45%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP272397.RAS1NoGWB3wxTqlbkmqHUllt6qGivLscGTCxxF-wIlYM8130_provenance.
• NP272687.RAUlqaRtimhLBBxyrUFjXXVztSpHmhYYh_a7lqPuipj1s130_assertion description "[BRAF mutation was mainly detected in SSA/P with dysplasia (95%), SSA/P (85%), microvesicular HP (76%), and traditional serrated adenoma (54%), whereas KRAS mutation was present mainly in goblet cell HP (50%) and in tubulovillous adenoma (45%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP272687.RAUlqaRtimhLBBxyrUFjXXVztSpHmhYYh_a7lqPuipj1s130_provenance.
• NP279848.RAYfU956iZ34gJY5CR7IXG-jOkvDeWelb3JEet1_LIWOk130_assertion description "[BRAF mutation was mainly detected in SSA/P with dysplasia (95%), SSA/P (85%), microvesicular HP (76%), and traditional serrated adenoma (54%), whereas KRAS mutation was present mainly in goblet cell HP (50%) and in tubulovillous adenoma (45%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP279848.RAYfU956iZ34gJY5CR7IXG-jOkvDeWelb3JEet1_LIWOk130_provenance.
• NP279903.RAWg4ixX43LZweLQU24fIyb2ZRvqZCdzPbygoS_QMUClU130_assertion description "[BRAF mutation was mainly detected in SSA/P with dysplasia (95%), SSA/P (85%), microvesicular HP (76%), and traditional serrated adenoma (54%), whereas KRAS mutation was present mainly in goblet cell HP (50%) and in tubulovillous adenoma (45%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP279903.RAWg4ixX43LZweLQU24fIyb2ZRvqZCdzPbygoS_QMUClU130_provenance.
• NP713381.RARG3LQiUpqFCUCowIuhd_Z2Mx-xfypBxARQ2WkIlEOE4130_assertion description "[BRAF mutation was mainly detected in SSA/P with dysplasia (95%), SSA/P (85%), microvesicular HP (76%), and traditional serrated adenoma (54%), whereas KRAS mutation was present mainly in goblet cell HP (50%) and in tubulovillous adenoma (45%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP713381.RARG3LQiUpqFCUCowIuhd_Z2Mx-xfypBxARQ2WkIlEOE4130_provenance.
• NP975582.RARugT0pZk4p7Z_EvVevyffetNJMS5gOPC_o0t7AAldbM130_assertion description "[BRAF mutation was mainly detected in SSA/P with dysplasia (95%), SSA/P (85%), microvesicular HP (76%), and traditional serrated adenoma (54%), whereas KRAS mutation was present mainly in goblet cell HP (50%) and in tubulovillous adenoma (45%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP975582.RARugT0pZk4p7Z_EvVevyffetNJMS5gOPC_o0t7AAldbM130_provenance.
• NP975589.RAcyHI0L3ktulc4Hb9EXDMIrShRnMsq8aKoEbOPpEYJls130_assertion description "[BRAF mutation was mainly detected in SSA/P with dysplasia (95%), SSA/P (85%), microvesicular HP (76%), and traditional serrated adenoma (54%), whereas KRAS mutation was present mainly in goblet cell HP (50%) and in tubulovillous adenoma (45%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP975589.RAcyHI0L3ktulc4Hb9EXDMIrShRnMsq8aKoEbOPpEYJls130_provenance.
• NP713390.RApmE2Xf4QHUppKQW4Wdyy8w4ohGl1T94ulrORfVTNaqo130_assertion description "[BRAF mutation was mainly detected in SSA/P with dysplasia (95%), SSA/P (85%), microvesicular HP (76%), and traditional serrated adenoma (54%), whereas KRAS mutation was present mainly in goblet cell HP (50%) and in tubulovillous adenoma (45%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP713390.RApmE2Xf4QHUppKQW4Wdyy8w4ohGl1T94ulrORfVTNaqo130_provenance.
• NP279857.RAtsL9fJr2YOK69vDW0WWjN0Gl4qi3HunyHbtrxwfBb1Y130_assertion description "[BRAF mutation was mainly detected in SSA/P with dysplasia (95%), SSA/P (85%), microvesicular HP (76%), and traditional serrated adenoma (54%), whereas KRAS mutation was present mainly in goblet cell HP (50%) and in tubulovillous adenoma (45%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP279857.RAtsL9fJr2YOK69vDW0WWjN0Gl4qi3HunyHbtrxwfBb1Y130_provenance.
• NP272382.RAA_GZMtYgzziITDxh4wD4RYyotBtzT-pU_FU_X3VI9kY130_assertion description "[BRAF mutation was mainly detected in SSA/P with dysplasia (95%), SSA/P (85%), microvesicular HP (76%), and traditional serrated adenoma (54%), whereas KRAS mutation was present mainly in goblet cell HP (50%) and in tubulovillous adenoma (45%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP272382.RAA_GZMtYgzziITDxh4wD4RYyotBtzT-pU_FU_X3VI9kY130_provenance.
• NP975575.RApUADhj83deWNzirgwDh3r7lHYf_HTgFukiCoOxXRJ4E130_assertion description "[BRAF mutation was mainly detected in SSA/P with dysplasia (95%), SSA/P (85%), microvesicular HP (76%), and traditional serrated adenoma (54%), whereas KRAS mutation was present mainly in goblet cell HP (50%) and in tubulovillous adenoma (45%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP975575.RApUADhj83deWNzirgwDh3r7lHYf_HTgFukiCoOxXRJ4E130_provenance.
• NP975576.RAqb6vOqq3i-GQ2rM83J31pdSeh3xqq7VxpczAgVl2c5M130_assertion description "[BRAF mutation was mainly detected in SSA/P with dysplasia (95%), SSA/P (85%), microvesicular HP (76%), and traditional serrated adenoma (54%), whereas KRAS mutation was present mainly in goblet cell HP (50%) and in tubulovillous adenoma (45%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP975576.RAqb6vOqq3i-GQ2rM83J31pdSeh3xqq7VxpczAgVl2c5M130_provenance.
• NP975581.RAty9Pk6oBhzhM9ihknB4nghOWPLRk8M_urUP6d5sTl8I130_assertion description "[BRAF mutation was mainly detected in SSA/P with dysplasia (95%), SSA/P (85%), microvesicular HP (76%), and traditional serrated adenoma (54%), whereas KRAS mutation was present mainly in goblet cell HP (50%) and in tubulovillous adenoma (45%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP975581.RAty9Pk6oBhzhM9ihknB4nghOWPLRk8M_urUP6d5sTl8I130_provenance.
• NP975583.RApKdumodBD3ivRo0wwVKqPdDEcDOw2PtdWBFLNhXX_UM130_assertion description "[BRAF mutation was mainly detected in SSA/P with dysplasia (95%), SSA/P (85%), microvesicular HP (76%), and traditional serrated adenoma (54%), whereas KRAS mutation was present mainly in goblet cell HP (50%) and in tubulovillous adenoma (45%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP975583.RApKdumodBD3ivRo0wwVKqPdDEcDOw2PtdWBFLNhXX_UM130_provenance.
• NP527745.RA1YulNneYiyfSGVFdgch6o96VR41osRZoPy4oQ7RghCo130_assertion description "[BRAF mutation was mainly detected in SSA/P with dysplasia (95%), SSA/P (85%), microvesicular HP (76%), and traditional serrated adenoma (54%), whereas KRAS mutation was present mainly in goblet cell HP (50%) and in tubulovillous adenoma (45%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP527745.RA1YulNneYiyfSGVFdgch6o96VR41osRZoPy4oQ7RghCo130_provenance.
• NP528045.RAI9h8OvrS1ZBAoGl-Sn3yxgg-LTVe_8pbWrS0V8wBA4A130_assertion description "[BRAF mutation was mainly detected in SSA/P with dysplasia (95%), SSA/P (85%), microvesicular HP (76%), and traditional serrated adenoma (54%), whereas KRAS mutation was present mainly in goblet cell HP (50%) and in tubulovillous adenoma (45%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP528045.RAI9h8OvrS1ZBAoGl-Sn3yxgg-LTVe_8pbWrS0V8wBA4A130_provenance.
• NP713422.RAwpRJkBUvmx5xhlQHOVHZ-FzaP6Ai1KX3IOUShTr-tJw130_assertion description "[BRAF mutation was mainly detected in SSA/P with dysplasia (95%), SSA/P (85%), microvesicular HP (76%), and traditional serrated adenoma (54%), whereas KRAS mutation was present mainly in goblet cell HP (50%) and in tubulovillous adenoma (45%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP713422.RAwpRJkBUvmx5xhlQHOVHZ-FzaP6Ai1KX3IOUShTr-tJw130_provenance.
• NP975572.RAPRUaTwtx6yGou-FrRHqC0Hahg2KnR9660HC1ZJlTMbA130_assertion description "[BRAF mutation was mainly detected in SSA/P with dysplasia (95%), SSA/P (85%), microvesicular HP (76%), and traditional serrated adenoma (54%), whereas KRAS mutation was present mainly in goblet cell HP (50%) and in tubulovillous adenoma (45%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP975572.RAPRUaTwtx6yGou-FrRHqC0Hahg2KnR9660HC1ZJlTMbA130_provenance.
• NP975573.RAIXLYnqaRIK9EN6XCoqmeCCZBZi_d7PnGWBUdHMZtyKE130_assertion description "[BRAF mutation was mainly detected in SSA/P with dysplasia (95%), SSA/P (85%), microvesicular HP (76%), and traditional serrated adenoma (54%), whereas KRAS mutation was present mainly in goblet cell HP (50%) and in tubulovillous adenoma (45%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP975573.RAIXLYnqaRIK9EN6XCoqmeCCZBZi_d7PnGWBUdHMZtyKE130_provenance.
• NP975580.RAIxZSAM_bu_KqMlmCgYT8aT1Eb8USwcBaHpgRCfwlSSc130_assertion description "[BRAF mutation was mainly detected in SSA/P with dysplasia (95%), SSA/P (85%), microvesicular HP (76%), and traditional serrated adenoma (54%), whereas KRAS mutation was present mainly in goblet cell HP (50%) and in tubulovillous adenoma (45%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP975580.RAIxZSAM_bu_KqMlmCgYT8aT1Eb8USwcBaHpgRCfwlSSc130_provenance.
• NP975587.RANOfjN5FTts2RMjH-A9z6zUDs_ihMS80Phw4QAddS_b0130_assertion description "[BRAF mutation was mainly detected in SSA/P with dysplasia (95%), SSA/P (85%), microvesicular HP (76%), and traditional serrated adenoma (54%), whereas KRAS mutation was present mainly in goblet cell HP (50%) and in tubulovillous adenoma (45%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP975587.RANOfjN5FTts2RMjH-A9z6zUDs_ihMS80Phw4QAddS_b0130_provenance.
• NP975577.RA1rYsrkqZatbgrX55MnXQ2EFt5BftRsIQ0CrzuTmt1n0130_assertion description "[BRAF mutation was mainly detected in SSA/P with dysplasia (95%), SSA/P (85%), microvesicular HP (76%), and traditional serrated adenoma (54%), whereas KRAS mutation was present mainly in goblet cell HP (50%) and in tubulovillous adenoma (45%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP975577.RA1rYsrkqZatbgrX55MnXQ2EFt5BftRsIQ0CrzuTmt1n0130_provenance.
• NP975586.RA4LuC0oUl68E_clATeCZW73JV6o_YTxOK5s7P-NaJ0dI130_assertion description "[BRAF mutation was mainly detected in SSA/P with dysplasia (95%), SSA/P (85%), microvesicular HP (76%), and traditional serrated adenoma (54%), whereas KRAS mutation was present mainly in goblet cell HP (50%) and in tubulovillous adenoma (45%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP975586.RA4LuC0oUl68E_clATeCZW73JV6o_YTxOK5s7P-NaJ0dI130_provenance.